Johnson & Johnson (J&J) is close to settling claims involving a significant portion of the Levaquin multidistrict litigation (MDL).
Bloomberg reports the proposed agreement involves 845 plaintiffs who alleged that J&J and its Ortho-McNeil Pharmaceutical unit failed to warn about the risk of serious tendon damage from the antibiotic Levaquin.
The amount the company has to pay for settlement is confidential as yet, according to a recent filing made in Minnesota federal court. The settlement is likely to conclude within the next two weeks. The Levaquin MDL includes 1,923 pending cases.
The filing states that the company faces more than 3,400 state and federal lawsuits for tendon injuries from the drug, reports Bloomberg. It also says that an additional 190 plaintiffs have started settlement discussions.
Johnson & Johnson is also in settlement discussions that resolve the consolidated proceedings of a majority of Levaquin complaints pending in New Jersey court, according to Law360 (subscription required). There are 1,509 cases active in the New Jersey litigation.
J&J has won three of the four Levaquin cases that have gone to trial, reports Bloomberg.